Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“Fourth NMPA approval for disitamab vedotin (DV):
DV is now approved in China for:
- HER2-overexpressing gastric cancer
- HER2-overexpressing urothelial carcinoma
- HER2-positive breast cancer with liver metastases
- HER2-low expressing breast cancer with liver metastases.”
Other articles featuring Raffaele Colombo on OncoDaily.